KESETT

KESETT

Ketamine add-on therapy for Established Status Epilepticus Treatment Trial

|

1UG3NS131532-01A1


Status: Pre-Enrollment

Trial Updates


New KESETT EFIC Resources

There are new resources available on the EFIC tab of the KESETT website. Please review the following documents found on this page:

Memo: Discussion of KESETT at Community Events Prior to CIRB review

Please see the memo from KESETT Leadership regarding the discussion of KESETT at community events prior to CIRB review: To: KESETT Sites From: KESETT Leadership Re: Discussion of KESETT at …

KESETT – New Resource in the Workbench

We have added a new resource to the KESETT workbench. You can find the archive of the slides presented at the monthly SIREN study coordinator meeting in the workbench under …

Overview


Ketamine add-on therapy for Established Status Epilepticus Treatment Trial (KESETT)


A multicenter, randomized, blinded study of treatment of patients with benzodiazepine-refractory status epilepticus in the emergency department, with either levetiracetam or levetiracetam combined with 1 mg/kg or 3 mg/kg dose ketamine to determine which treatment leads to more effective control of status epilepticus.

Learn About KESETT

Presented by Robert Silbergleit

Slides

Contact


Emergency 24-Hour Study Hotline:

To be announced

Education (training, website access, material development, technical support):

Courtney Miller ([email protected]) – Education Coordinator, or [email protected]

WebDCU Support (user account requests, technical support, CRF completion):

Sara Meyer ([email protected]) (843) 792-1599 & Riley Luckmann ([email protected]) (843) 792-1599

Site Management & General Inquiries:

Vincent Cervantes ([email protected]) or [email protected]

Finances:

Valerie Stevenson ([email protected])

For a comprehensive list of contacts:

SIREN COntact Page